Regulation desk · Compounding law
503A vs 503B: the two legal lanes for compounded peptides
The difference between 503A pharmacies and 503B outsourcing facilities, the bulk-ingredient rules, and why they decide whether a peptide can be compounded.
The short answer ·
503A covers state-licensed pharmacies and physicians compounding for an identified patient on a prescription. They may use a bulk ingredient only if it has a USP/NF monograph, is part of an FDA-approved drug, or is on FDA's 503A bulks list.
503B covers FDA-registered outsourcing facilities that follow CGMP and may compound without patient-specific prescriptions. They may use bulk ingredients on the 503B list (for clinical need) or ones that appear on FDA's drug-shortage list.
Compounding sits between an approved drug and an unapproved one. A compounded drug is not FDA-approved, but if it meets the statute’s conditions it is exempt from three requirements that would otherwise apply: premarket approval, labeling with adequate directions for use, and (for 503A) current good manufacturing practice. If any condition is missed, the exemptions fall away and the product is treated as an unapproved new drug.
How do 503A and 503B compare side by side?
| 503A | 503B | |
|---|---|---|
| Who | State-licensed pharmacy or physician | FDA-registered outsourcing facility |
| Prescription | Required, for an identified individual patient | Not required per patient (can supply clinics/hospitals) |
| Quality standard | USP chapters and state board rules | Federal CGMP; FDA inspection |
| Primary regulator | State board of pharmacy (FDA retains authority) | FDA |
| Bulk substances allowed | USP/NF monograph; component of an approved drug; or on 503A bulks list | On 503B bulks list (clinical need) or on FDA drug-shortage list |
| Copies of approved drugs | Not “regularly or in inordinate amounts” | Not unless on shortage list |
| Interim categories | 503A Categories 1/2/3 | 503B Categories 1/2/3 |
Which bulk ingredients can compounders use?
For peptides, the bulk-substance rule is the one that matters most. A 503A pharmacy needs a lawful ingredient before it can make a lawful product. The ingredient must also be made by an FDA-registered establishment and come with a valid certificate of analysis. Polsinelli’s 2026 analysis warns that bulk substances “marketed as ‘research grade’ or ‘research use only’ may present heightened regulatory and quality risk” for pharmacies.
Most popular research peptides fail all three 503A routes today. They have no USP monograph, they are not components of approved drugs, and they are not on the bulks list. That is why the 2026 debate is about the bulks list and an interim enforcement policy (tracker).
How are approved-drug peptides different?
Peptides that are components of approved drugs can, in principle, be compounded under 503A, subject to the “essentially a copy” limits. Examples are semaglutide, tirzepatide, tesamorelin and bremelanotide. During the 2022-2025 GLP-1 shortages, the shortage exception let compounders make semaglutide and tirzepatide at scale. That ended with the shortages (explainer).
Where do research-use-only sellers fit?
They do not fit either lane. A website shipping vials labeled “not for human use” is not a pharmacy filling prescriptions or a registered outsourcing facility. When FDA concludes such products are intended for people, it treats them as unapproved new drugs under section 505(a) (warning letters explained).
In the news
All news
Frequently asked questions
Can a compounding pharmacy make BPC-157?
Only if BPC-157 qualifies as a bulk substance under 503A. It has no USP monograph, is not a component of an approved drug, and is not on the 503A bulks list as of October 19, 2026. An interim access policy is under OMB review.
What is an outsourcing facility?
A compounder registered with FDA under section 503B. It must follow current good manufacturing practice, is inspected by FDA on a risk basis, and can make larger batches without patient-specific prescriptions.
Can compounded drugs copy FDA-approved drugs?
Generally no. Both sections restrict compounding drugs that are essentially copies of approved drugs, except in defined situations such as when the drug is on FDA's shortage list.
Sources
5 linked records- [1] Bulk Drug Substances Used in Compounding Under Section 503A U.S. FDA Primary record
- [2] Human Drug Compounding (FDA hub) U.S. FDA Primary record
- [3] 21 U.S.C. 353a (section 503A) LII / Cornell Primary record
- [4] 21 U.S.C. 353b (section 503B) LII / Cornell Primary record
- [5] Tiny Chains, Big Changes? (Polsinelli) Polsinelli ·
This explainer is general information about law and laboratory methods, not legal or medical advice. Amino Wire does not provide dosing information. Spotted an error? See our corrections policy.